MedPath

Rocuronium

Generic Name
Rocuronium
Drug Type
Small Molecule
Chemical Formula
C32H53N2O4
CAS Number
143558-00-3
Unique Ingredient Identifier
WRE554RFEZ
Background

Rocuronium (rapid onset-curonium) is a desacetoxy analogue of vecuronium with a more rapid onset of action. It is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anaesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Introduced in 1994, rocuronium has rapid onset, and intermediate duration of action. It is commonly marketed under the trade names Zemuron and Esmeron. The drug is associated with the risk of developing allergic reactions in some high-risk patients, such as those with asthma. However, there was a similar incidence of allergic reactions associated with other non-depolarizing neuromuscular blocking agents. Sugammadex is a γ-cyclodextrin derivative that has been introduced as a novel agent to reverse the action of rocuronium.

Indication

For inpatients and outpatients as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

Associated Conditions
Muscle fasciculation caused by succinylcholine
Associated Therapies
Curarization therapy, Neuromuscular blocking therapy, Facilitation of small bowel intubation therapy

Succinylcholine Versus Rocuronium for Emergency Intubation in Intensive Care

Phase 4
Completed
Conditions
Intubation
Interventions
First Posted Date
2006-07-21
Last Posted Date
2011-12-15
Lead Sponsor
University Hospital, Basel, Switzerland
Target Recruit Count
420
Registration Number
NCT00355368
Locations
🇨🇭

Department of Medical Intensive Care; University of Basel, Basel, BS, Switzerland

Use of Sugammadex at the End of Case in Routine Anesthesia (MK-8616-023)

Phase 3
Completed
Conditions
Anesthesia, General
Interventions
First Posted Date
2006-03-03
Last Posted Date
2019-03-27
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
224
Registration Number
NCT00298831

A Study to Determine the Dose Requirements of Rocuronium Bromide (Zemuron®) in Pediatric and Adolescent Subjects (21048)(COMPLETED)(P05797)

First Posted Date
2005-07-28
Last Posted Date
2016-08-24
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
149
Registration Number
NCT00124735

A Study to Compare Different Intubating Doses of Zemuron in Pediatric and Adolescent Subjects Under General Anesthesia

Phase 3
Completed
Conditions
Anesthesia
Interventions
First Posted Date
2005-07-28
Last Posted Date
2015-06-01
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
207
Registration Number
NCT00124722
© Copyright 2025. All Rights Reserved by MedPath